Overview

Liraglutide Effect in Atrial Fibrillation

Status:
Recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
The goal (or purpose) of this study is to evaluate (study) a new way to stabilize (steady) the activity between the fat deposits surrounding the heart and the left atrium. To reduce the amount of EAT, this study will use a medication called Liraglutide. This medication is known to work on fat deposits and produce weight loss. The investigator is conducting this study to find out if Liraglutide will reduce the fat deposits surrounding the participant's heart, and stabilize (and perhaps reduce or eliminate) atrial fibrillation activity.
Phase:
Phase 4
Details
Lead Sponsor:
University of Miami
Treatments:
Anti-Arrhythmia Agents
Liraglutide